Tonazocine
 | |
| Systematic (IUPAC) name | |
|---|---|
| 1-[(2S,6R,11S)-8-hydroxy-3,6,11-trimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-11-yl]octan-3-one | |
| Clinical data | |
| |
| Identifiers | |
| 71461-18-2 | |
| None | |
| PubChem | CID 72177 |
| ChemSpider | 65150 |
| UNII | J356A16LLK |
| Chemical data | |
| Formula | C23H35NO2 |
| 357.530 g/mol | |
|
SMILES
| |
| |
Tonazocine (WIN-42,156) is an opioid analgesic of the benzomorphan family which made it to phase II clinical trials for the treatment of postoperative pain,[1] but development was apparently ceased and ultimately it was never marketed. Tonazocine is a partial agonist at both the mu-opioid and delta-opioid receptors, but acting more like an antagonist at the former and more like an agonist at the latter.[2][3] It lacks most of the side effects of other opioids such as adverse effects on the cardiovascular system and respiratory depression, but it can cause sedation (although to a lesser degree of typical opioids), and in some patients it may induce hallucinations.[4]
See also
References
- ↑ American Chemical Society. Division of Medicinal Chemistry (1990). Annual Reports in Medicinal Chemistry. Academic Press. p. 12. ISBN 978-0-12-040525-1. Retrieved 30 November 2011.
- ↑ Ward SJ, Pierson AK, Michne WF (February 1985). "Pharmacological profiles of tonazocine (Win 42156) and zenazocine (Win 42964)". Neuropeptides 5 (4-6): 375–8. doi:10.1016/0143-4179(85)90032-0. PMID 2860595.
- ↑ Hudzik TJ, Howell A, Payza K, Cross AJ (May 2000). "Antiparkinson potential of delta-opioid receptor agonists". European Journal of Pharmacology 396 (2-3): 101–7. doi:10.1016/S0014-2999(00)00209-0. PMID 10822062.
- ↑ Jeffrey K. Aronson (30 November 2009). Meyler's Side Effects of Analgesics and Anti-inflammatory Drugs. Elsevier. p. 154. ISBN 978-0-444-53273-2. Retrieved 30 November 2011.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||